PitchSend

Nuvectis Pharma Investor Presentation Deck

NXP800 Mechanism of Action NXP800 is a GCN2 kinase activator NXP800 activates the GCN2 kinase, resulting in: Chronic activation of the integrated stress response (ISR) Inhibition of cap-dependent translation Chronic activation of the ISR results in cancer cell death * A vulnerability of ARID1a-mutated tumors is their increased dependence on translation, which is exploited by NXP800 NuvectisPharma, Inc. Recognition by GCN2 Non- acylated tRNA NXP800 Stalled GCN2 ribosome GCN2 GCN2 activation Created with BioRender.com elF2a phosphorylation elF2a Selective ATF4 translation ATF4 Dimerization partner Cap-dependent translation ATF4 Translational switch - including HSF1 regulated proteins Chronic activation: Autophagic and apoptotic cell death (CHOP and other validated PD markers) Stress-induced genes x 0 8

View entire presentation